Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Sirona Biochem Corp
V.SBM
Alternate Symbol(s):
SRBCF
Healthcare
Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to...
large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:SBM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
...
Next
(2113)
•••
tylerreddick
X
View Profile
View Bullboard History
Comment by
tylerreddick
on Oct 12, 2023 9:49pm
RE:RE:RE:New record!
" Once they start booking revenue from the Abbvie/Allergan deal " By the look of the share price, the Abbvie "deal" looks like another fiasco just like the R&F complete and
...more
(1176)
•••
Pandora
X
View Profile
View Bullboard History
Comment by
Pandora
on Oct 12, 2023 6:14pm
RE:RE:RE:New record!
"Once they start booking revenue from the Abbvie/Allergan deal,...." And that's the statement of the day, the week, the month, the year! ONCE!
(101)
•••
biorun
X
View Profile
View Bullboard History
Comment by
biorun
on Oct 12, 2023 2:37pm
RE:RE:New record!
There is plenty to chose from the pipeline to move forward here. Howard's insatiable appetite for perfection has a way of keeping things constipated when they should be flowing like an overdose of
...more
(10)
•••
PeterG
X
View Profile
View Bullboard History
Comment by
PeterG
on Oct 12, 2023 2:20pm
RE:New record!
No money, no news, no employee anymore!! Historical low and Chris and Howard are doing nothing against that situation. Crazy times. Two months ago , Chris promised to improve shareholder
...more
(77)
•••
Pareto8020
X
View Profile
View Bullboard History
Post by
Pareto8020
on Oct 12, 2023 9:45am
New record!
8.5 cents..... must be close to a 10 year record low. Any other company may consider shaking up the C-Suite after such a dismal performance. But not SBM - just keep smiling and axe an underling
...more
(38)
•••
Turtle4
X
View Profile
View Bullboard History
Comment by
Turtle4
on Oct 05, 2023 11:09am
RE:2023 a write off?
JUNE 15TH, 2022 Sirona Biochem Initiates Significant Corporate Changes Now that Sirona Biochem has closed exclusive global licencing agreement with Allergan Aesthetics, the next steps for
...more
(77)
•••
Pareto8020
X
View Profile
View Bullboard History
Post by
Pareto8020
on Oct 05, 2023 10:04am
2023 a write off?
No news, no revenue..... is Howard finally going to pull that rabbit out of his hat this year or do us poor shareholders have to endure until 2024? They really just need to start getting that revenue
...more
(101)
•••
biorun
X
View Profile
View Bullboard History
Comment by
biorun
on Oct 01, 2023 9:10pm
RE:RE:RE:Fins on sedar
The R&D tax grant receivable is unusually high it appears. What is the government now feeling sorry for them?... either way, it complements the cash position, I assume this quarter.
(2175)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Oct 01, 2023 6:34pm
RE:RE:RE:RE:Fins on sedar
Irregularly, not periodically
(2175)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Oct 01, 2023 6:31pm
RE:RE:RE:Fins on sedar
R&D tax credits (source of cash) seem to be paid out periodically... Change R&D tax credit receivable Qtr ending
...more
(2175)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Oct 01, 2023 5:48pm
RE:RE:Fins on sedar
Co chose to do a $1.5 million debenture issue in April which was oversubscribed. Why not more? Do they expect a milestone payment from Abbvie shortly?
(2175)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Oct 01, 2023 5:18pm
RE:RE:Fins on sedar
7.45 million options exercisable at $0.16/$0.17 until Jan /jun 2025. Insiders need to exercise early to keep the lights on.
(1)
•••
sakinny3
X
View Profile
View Bullboard History
Comment by
sakinny3
on Oct 01, 2023 4:35pm
RE:Fins on sedar
300,000 cash left at the end of July, won't have much of that left in the bank now. Will run out of cash very soon
(38)
•••
Turtle4
X
View Profile
View Bullboard History
Comment by
Turtle4
on Oct 01, 2023 2:52pm
RE:RE:Fins on sedar
Thx for the list! I would say they sold 12Kg now.
Prev
...
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Options Trading for Retiring: Key Strategies in Balancing Retirement Income
One Property, One Focus on Advancing this Gold Project in Ontario